A Geistlich technology originally developed for oral applications can now also be used more broadly in the face, head and neck. The Swiss family-owned company has received European approval for the use of Geistlich Mucograft® collagen matrix in extraoral areas. For patients with skin defects in the face, head and neck this provides an advanced and simple alternative to grafting procedures in which the patient's own skin is harvested.
Geistlich has received this approval for the expanded anatomical placement of Geistlich Mucograft® in accordance with the European Medical Device Regulation (MDR). The product for the regeneration of oral mucosa is now also approved for the treatment and reconstruction of skin defects outside the mouth. Diego Gabathuler, CEO of Geistlich, says, "With this new treatment, Geistlich is strengthening our portfolio in the field of regeneration by offering new solutions for healing of dermal wounds."
Geistlich Mucograft® outcomes are equivalent to skin grafting
Many people suffer from skin defects in the head and neck area caused by various types of skin cancer or injuries. Wound treatment in these areas is complex and often takes time, partly due to the importance of aesthetics. Transplantation of autologous tissue and local flap grafting remain the current gold standard treatments following tumor removal. In these procedures tissue is removed from the patient, creating an additional defect that itself requires treatment. In the CE approval study, it was shown that the use of Geistlich Mucograft® after surgical removal of... [READ MORE]
Earlier this year, Samsung established the era of mobile AI with the launch of the Galaxy S24 series and committed to introducing Galaxy AI1 to a wider range of devices....
A Geistlich technology originally developed for oral applications can now also be used more broadly in the face, head and neck. The Swiss family-owned company has receive...
A virtual marketplace leading your business into the future
